Study guide

20.1 Acute Respiratory Distress Syndrome (ARDS) and Mechanical Ventilation Strategies

EDAIC Part I European Diploma in Anaesthesiology and Intensive Care

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: The EDAIC Part I Examination

1.1 EDAIC Part I Exam Format, Scoring and Multiple True/False Strategy

2 Chapter 2: Anatomy for Anaesthesia and Intensive Care

2.1 Functional Anatomy of the Upper Airway, Larynx, and Tracheobronchial Tree 2.2 Neuraxial Anatomy: Spine, Spinal Cord, Meninges, and Spaces 2.3 Vascular Anatomy for Central and Peripheral Cannulation 2.4 Peripheral Nerve Plexuses and Autonomic Nervous System Pathways 2.5 Thoracic Anatomy: Chest Wall, Intercostal Spaces, Pleura, Mediastinum and Heart

3 Chapter 3: Respiratory and Cardiovascular Physiology

3.1 Respiratory Mechanics, Lung Volumes, and Work of Breathing 3.2 Ventilation-Perfusion Relationships, Shunt, and Gas Exchange 3.3 Control of Breathing, Hypoxia, Altitude and Hyperbaric Physiology 3.4 Cardiac Cycle, Electrophysiology, and Ventricular Function 3.5 Vascular Resistance, Microcirculation, and Systemic Hemodynamics

4 Chapter 4: Neurophysiology, Renal, Hepatic and Acid-Base Physiology

4.1 Cerebral Blood Flow, Intracranial Pressure, and CSF Dynamics 4.2 Renal Physiology, Glomerular Filtration, and Tubular Transport 4.3 Hepatic Blood Flow, Metabolism, and Clearance 4.4 Acid-Base Regulation, Buffering Systems, and Stewart Approach

5 Chapter 5: Endocrine and Haematological Physiology

5.1 Endocrine Physiology and the Neuroendocrine Stress Response 5.2 Haemostasis Physiology, Coagulation Testing and Inherited Bleeding Disorders

6 Chapter 6: Special Patient Physiology: Maternal, Paediatric and Geriatric

6.1 Maternal Physiological Adaptations to Pregnancy and Uteroplacental Flow 6.2 Neonatal and Paediatric Physiological Differences 6.3 Physiological Changes of Ageing and Thermoregulation

7 Chapter 7: General Pharmacological Principles and Inhalational Anaesthetics

7.1 Pharmacokinetic Principles, Compartmental Models, and Clearance 7.2 Pharmacodynamic Mechanisms, Receptor Theory, and Drug Interactions 7.3 Physical Properties, Uptake, and Distribution of Volatile Anaesthetics 7.4 Minimum Alveolar Concentration (MAC), Organ Effects, and Toxicity

8 Chapter 8: Intravenous Agents, Neuromuscular Blockade and Analgesics

8.1 Intravenous Induction Agents: Propofol, Etomidate, Ketamine, and Barbiturates 8.2 Neuromuscular Blocking Agents: Depolarizing and Non-Depolarizing Drugs 8.3 Neuromuscular Monitoring and Reversal: Anticholinesterases and Sugammadex 8.4 Opioid Pharmacology, Receptors, and Non-Opioid Analgesic Agents

9 Chapter 9: Cardiovascular Drugs, Autonomic Pharmacology and Local Anaesthetics

9.1 Inotropes, Vasopressors, and Inodilators in Perioperative Care 9.2 Antiarrhythmic, Antihypertensive, and Beta-Adrenergic Antagonist Drugs 9.3 Local Anaesthetic Pharmacology, Toxicity (LAST), and Lipid Emulsion Therapy

10 Chapter 10: Haematological and Internal Medicine Pharmacology

10.1 Anticoagulant, Antiplatelet and Haemostatic Drugs and Their Reversal 10.2 Internal Medicine Drugs: Endocrine, Respiratory, Psychiatric and Antiepileptic Agents and Their Anaesthetic Interactions

11 Chapter 11: Physics, Clinical Measurement and Medical Equipment

11.1 Physical Gas Laws, Fluid Dynamics, and Resistance Principles 11.2 Anaesthetic Machines, Gas Supply Pipelines, Cylinders, and Safety Mechanisms 11.3 Breathing Systems, Vaporizer Mechanics, and Scavenging Systems 11.4 Invasive and Non-Invasive Hemodynamic and Respiratory Monitoring

12 Chapter 12: Electrical Safety, Temperature, Humidity and Gas Analysis

12.1 Electricity, Electrical Safety, Diathermy, Defibrillation, Implanted Devices and Fire 12.2 Temperature Measurement, Humidity, Gas Analysis and SI Units

13 Chapter 13: Biostatistics, Clinical Trials and Evidence Appraisal

13.1 Descriptive Statistics, Distributions, and Parametric vs Non-Parametric Tests 13.2 Hypothesis Testing, Power, Type I/II Errors, and Confidence Intervals 13.3 Clinical Study Designs, Bias, and Diagnostic Test Performance (Sensitivity, Specificity, ROC)

14 Chapter 14: General Anaesthesia, Preoperative Evaluation and Airway Management

14.1 Preoperative Risk Assessment, Cardiovascular Risk Indices, and Fasting Guidelines 14.2 The Difficult Airway: Assessment, Algorithms, and Rescue Oxygenation 14.3 Intraoperative Fluid Therapy, Goal-Directed Hemodynamics, and Blood Conservation 14.4 Post-Anaesthesia Care Unit (PACU) Management, Emergence, and Postoperative Nausea/Vomiting

15 Chapter 15: Coexisting Disease and Preoperative Investigations

15.1 Interpreting Investigations: ECG, Chest Radiograph, Lung Function and Blood Tests 15.2 Coexisting Disease I: Asthma, COPD, Obstructive Sleep Apnoea, Obesity, Liver and Renal Disease 15.3 Endocrine Disease and Emergencies: Diabetes, DKA and HHS, Thyroid, Adrenal, Phaeochromocytoma and Carcinoid 15.4 Coexisting Disease II: Neuromuscular and Neurological Disease

16 Chapter 16: Subspecialty Anaesthesia: Cardiothoracic, Vascular and Neuroanaesthesia

16.1 Anaesthesia for Cardiac Surgery and Cardiopulmonary Bypass Management 16.2 Thoracic Anaesthesia, One-Lung Ventilation, and Major Vascular Surgery 16.3 Neuroanaesthesia: Craniotomy, Sitting Position, and Traumatic Brain Injury

17 Chapter 17: Obstetric, Paediatric and Ambulatory Anaesthesia

17.1 Obstetric Analgesia and Anaesthesia: Labour, Caesarean Delivery, and High-Risk Conditions 17.2 Paediatric Anaesthesia: Induction, Airway Management, and Emergencies 17.3 Ambulatory Day-Surgery Selection, Premedication, and Elderly Patient Anaesthesia

18 Chapter 18: Anaesthetic Complications and Specialty Settings

18.1 Anaesthetic Complications: Accidental Awareness, Aspiration, Positioning Injuries, Visual Loss and Dental Damage 18.2 Anaesthesia for ENT and Laser Airway Surgery, Ophthalmic Surgery, and Laparoscopic and Robotic Surgery

19 Chapter 19: Regional Anaesthesia and Acute/Chronic Pain Management

19.1 Neuraxial Techniques: Spinal, Epidural, and Caudal Anaesthesia 19.2 Upper and Lower Limb Peripheral Nerve and Fascial Plane Blocks 19.3 Multimodal Acute Postoperative Pain Management and ERAS Pathways 19.4 Chronic and Neuropathic Pain Syndromes and Interventional Management 19.5 Palliative Symptom Control, Psychological Aspects of Pain and Multidisciplinary Pain Management

20 Chapter 20: Intensive Care Medicine: Ventilation, Shock and Organ Support

20.1 Acute Respiratory Distress Syndrome (ARDS) and Mechanical Ventilation Strategies 20.2 Sepsis-3 Definitions, Septic Shock, and Hemodynamic Resuscitation 20.3 Acute Kidney Injury, Indications for Dialysis, and Continuous Renal Replacement Therapy 20.4 ICU Sedation, Delirium, Weaning, and Brain Death Determination

21 Chapter 21: Intensive Care Medicine: Admission, Nutrition, Infection and Electrolytes

21.1 ICU Admission, Severity Scoring, Nutrition and Routine Prophylaxis 21.2 Antimicrobial Therapy, Stewardship and ICU-Acquired Infections 21.3 Electrolyte Disorders: Sodium, Potassium, Calcium, Magnesium and Phosphate

22 Chapter 22: Intensive Care and Emergency Medicine: Neurocritical Care, Poisoning and Cardiorespiratory Emergencies

22.1 Neurocritical Care: Subarachnoid Haemorrhage, Stroke, Status Epilepticus and Acute Neuromuscular Failure 22.2 Acute Poisoning: Toxidromes, Decontamination and Specific Antidotes 22.3 Acute Cardiorespiratory Emergencies: Pulmonary Embolism, Acute Severe Asthma and COPD, Non-Invasive Support and Acute Heart Failure

23 Chapter 23: Resuscitation, Perioperative Emergencies and Professional Ethics

23.1 Advanced Life Support (ALS) Guidelines and Perioperative Cardiac Arrest 23.2 Perioperative Crises: Malignant Hyperthermia and Severe Anaphylaxis 23.3 Major Trauma, Hemorrhagic Shock, and Massive Transfusion Protocols 23.4 Professional Ethics, Informed Consent, Patient Safety, and Helsinki Declaration

24 Chapter 24: Newborn, Paediatric and Obstetric Emergencies

24.1 Newborn Life Support and Paediatric Life Support 24.2 Obstetric Emergencies: Maternal Collapse, Amniotic Fluid Embolism, Uterine Inversion and Resuscitative Hysterotomy

25 Chapter 25: Burns, Environmental Emergencies and Patient Transport

25.1 Burns, Inhalation Injury, Drowning, Hypothermia, Heat Illness and Decompression Illness 25.2 Prehospital Care and Intra- and Inter-Hospital Transport of the Critically Ill

20.1 Acute Respiratory Distress Syndrome (ARDS) and Mechanical Ventilation Strategies

Key Takeaways Explain This Topic AI

The Berlin 2012 definition classifies ARDS on PEEP ≥ 5 cm H 2 O \ge 5\text{ cm}\text{H}_2\text{O} ≥ 5 cm H 2 ​ O into Mild ( P a O 2 / F i O 2 201 − 300 mmHg P_a\text{O}_2/F_i\text{O}_2\text{ }201-300\text{ mmHg} P a ​ O 2 ​ / F i ​ O 2 ​ 201 − 300 mmHg ), Moderate ( P a O 2 / F i O 2 101 − 200 mmHg P_a\text{O}_2/F_i\text{O}_2\text{ }101-200\text{ mmHg} P a ​ O 2 ​ / F i ​ O 2 ​ 101 − 200 mmHg ), and Severe ( P a O 2 / F i O 2 ≤ 100 mmHg P_a\text{O}_2/F_i\text{O}_2\le 100\text{ mmHg} P a ​ O 2 ​ / F i ​ O 2 ​ ≤ 100 mmHg ) within 1 week of clinical insult.

Lung-protective ventilation mandates a low tidal volume of 6 mL/kg 6\text{ mL/kg} 6 mL/kg predicted body weight (PBW) and a plateau pressure ( P plat P_{\text{plat}} P plat ​ ) ≤ 30 cm H 2 O \le 30\text{ cm}\text{H}_2\text{O} ≤ 30 cm H 2 ​ O to prevent volutrauma and barotrauma.

Driving pressure ( Δ P = P plat − PEEP \Delta P = P_{\text{plat}} - \text{PEEP} Δ P = P plat ​ − PEEP ) reflects cyclic lung strain relative to compliance; targeting Δ P < 14 − 15 cm H 2 O \Delta P < 14-15\text{ cm}\text{H}_2\text{O} Δ P < 14 − 15 cm H 2 ​ O is the ventilatory metric most strongly linked to reduced mortality.

Prone positioning for ≥ 16 hours/day \ge 16\text{ hours/day} ≥ 16 hours/day in severe ARDS ( P a O 2 / F i O 2 < 150 mmHg P_a\text{O}_2/F_i\text{O}_2 < 150\text{ mmHg} P a ​ O 2 ​ / F i ​ O 2 ​ < 150 mmHg ) significantly reduces 28-day and 90-day mortality by homogenizing transpulmonary pressure gradients and recruiting dorsal lung units.

Last updated: October 2026

20.1 Acute Respiratory Distress Syndrome (ARDS) and Mechanical Ventilation Strategies

Acute Respiratory Distress Syndrome (ARDS) is a life-threatening form of acute, diffuse, inflammatory lung injury characterized by increased pulmonary vascular permeability, severe alveolar flooding, loss of aerated lung tissue, and refractory arterial hypoxemia. For the EDAIC Part I examination, candidates must master the diagnostic classification, pathobiology, mechanical ventilator mechanics, and evidence-based adjunctive interventions.

The Berlin Definition of ARDS (2012)

The Berlin definition refined the earlier American-European Consensus Conference (AECC) criteria by removing the ambiguous term "acute lung injury" (ALI), mandating positive end-expiratory pressure (PEEP), and establishing three severity categories based on arterial oxygenation.

Diagnostic Category Berlin Consensus Criteria (2012)

Timing Acute onset within 1 week of a known clinical insult, or new/worsening respiratory symptoms.

Chest Imaging Bilateral opacities on chest radiograph or computed tomography (CT) not fully explained by pleural effusions, lobar/lung collapse, or nodules.

Origin of Edema Respiratory failure not fully explained by cardiac failure or fluid overload. Objective assessment (e.g., transthoracic or transesophageal echocardiography) is required if no clinical risk factor (such as sepsis, trauma, or pancreatitis) is present.

Oxygenation (on PEEP ≥ 5 cm H 2 O \ge 5\text{ cm}\text{H}_2\text{O} ≥ 5 cm H 2 ​ O ) Mild ARDS: 200 < P a O 2 / F i O 2 ≤ 300 mmHg 200 < P_a\text{O}_2/F_i\text{O}_2 \le 300\text{ mmHg} 200 < P a ​ O 2 ​ / F i ​ O 2 ​ ≤ 300 mmHg ; Moderate ARDS: 100 < P a O 2 / F i O 2 ≤ 200 mmHg 100 < P_a\text{O}_2/F_i\text{O}_2 \le 200\text{ mmHg} 100 < P a ​ O 2 ​ / F i ​ O 2 ​ ≤ 200 mmHg ; Severe ARDS: P a O 2 / F i O 2 ≤ 100 mmHg P_a\text{O}_2/F_i\text{O}_2 \le 100\text{ mmHg} P a ​ O 2 ​ / F i ​ O 2 ​ ≤ 100 mmHg

Note on High Altitude: At altitudes above 1,000 metres, the P a O 2 / F i O 2 P_a\text{O}_2/F_i\text{O}_2 P a ​ O 2 ​ / F i ​ O 2 ​ ratio must be multiplied by ( Atmospheric Pressure in mmHg / 760 ) (\text{Atmospheric Pressure in mmHg} / 760) ( Atmospheric Pressure in mmHg /760 ) to standardize the severity grade.

The 2024 Global Definition of ARDS

A 2023 international consensus (Matthay et al., American Journal of Respiratory and Critical Care Medicine 2024) broadened the Berlin definition so that it can be applied to more patients and settings:

Non-intubated ARDS: Patients receiving high-flow nasal oxygen at ≥ 30 L/min \ge 30\text{ L/min} ≥ 30 L/min , or non-invasive ventilation/CPAP with end-expiratory pressure ≥ 5 cm H 2 O \ge 5\text{ cm}\text{H}_2\text{O} ≥ 5 cm H 2 ​ O , with P a O 2 / F i O 2 ≤ 300 mmHg P_a\text{O}_2/F_i\text{O}_2 \le 300\text{ mmHg} P a ​ O 2 ​ / F i ​ O 2 ​ ≤ 300 mmHg or S p O 2 / F i O 2 ≤ 315 S_p\text{O}_2/F_i\text{O}_2 \le 315 S p ​ O 2 ​ / F i ​ O 2 ​ ≤ 315 (the oxygen saturation ratio is valid only when S p O 2 ≤ 97 % S_p\text{O}_2 \le 97\% S p ​ O 2 ​ ≤ 97% ).

Intubated ARDS: Severity is graded as mild ( 200 < P a O 2 / F i O 2 ≤ 300 200 < P_a\text{O}_2/F_i\text{O}_2 \le 300 200 < P a ​ O 2 ​ / F i ​ O 2 ​ ≤ 300 or 235 < S p O 2 / F i O 2 ≤ 315 235 < S_p\text{O}_2/F_i\text{O}_2 \le 315 235 < S p ​ O 2 ​ / F i ​ O 2 ​ ≤ 315 ), moderate ( 100 < P a O 2 / F i O 2 ≤ 200 100 < P_a\text{O}_2/F_i\text{O}_2 \le 200 100 < P a ​ O 2 ​ / F i ​ O 2 ​ ≤ 200 or 148 < S p O 2 / F i O 2 ≤ 235 148 < S_p\text{O}_2/F_i\text{O}_2 \le 235 148 < S p ​ O 2 ​ / F i ​ O 2 ​ ≤ 235 ), or severe ( P a O 2 / F i O 2 ≤ 100 P_a\text{O}_2/F_i\text{O}_2 \le 100 P a ​ O 2 ​ / F i ​ O 2 ​ ≤ 100 or S p O 2 / F i O 2 ≤ 148 S_p\text{O}_2/F_i\text{O}_2 \le 148 S p ​ O 2 ​ / F i ​ O 2 ​ ≤ 148 ).

Imaging: Bilateral opacities on chest radiograph or CT, or bilateral B-lines and/or consolidation on lung ultrasound performed by a trained operator.

Resource-limited settings: Neither PEEP, a minimum oxygen flow rate, nor a specific respiratory support device is required; S p O 2 / F i O 2 ≤ 315 S_p\text{O}_2/F_i\text{O}_2 \le 315 S p ​ O 2 ​ / F i ​ O 2 ​ ≤ 315 with bilateral opacities is sufficient.

Triphasic Pathophysiology of ARDS

The morphological hallmark of ARDS is diffuse alveolar damage (DAD) , which evolves through three continuous, overlapping phases:

1. Exudative Phase (Days 0–7)

Alveolar-Capillary Barrier Disruption: Activation of resident pulmonary macrophages triggers release of pro-inflammatory cytokines (tumor necrosis factor-alpha [TNF- α \alpha α ], interleukin-1beta [IL-1 β \beta β ], and interleukin-8 [CXCL8]), recruiting activated neutrophils into the interstitium and alveoli.

Endothelial and Epithelial Necrosis: Neutrophil proteases and reactive oxygen species cause widespread microvascular endothelial permeability and necrosis of alveolar type I pneumocytes (which cover 90 % 90\% 90% of the alveolar surface).

Protein-Rich Flooding and Hyaline Membranes: Extravasation of protein-rich fluid into the alveolar space inactivates pulmonary surfactant. Denuded basement membranes become coated with fibrin, cellular debris, and plasma proteins, forming eosinophilic hyaline membranes .

Microvascular Thrombosis: Platelet activation and fibrin deposition within the pulmonary capillary bed create microvascular occlusions, increasing physiological dead space ( V D / V T V_D/V_T V D ​ / V T ​ ) and precipitating acute pulmonary hypertension.

2. Proliferative Phase (Days 7–21)

Epithelial Repair: Marked hyperplasia and proliferation of type II pneumocytes along the denuded alveolar basement membranes. These cells act as progenitor stem cells, differentiating into type I pneumocytes to restore the epithelial barrier and re-establish active sodium and water transport via apical epithelial sodium channels ( E N a C ENaC EN a C ) and basolateral N a + / K + Na^+/K^+ N a + / K + -ATPase pumps.

Fibroblast Activation: Infiltration of fibroblasts and myofibroblasts produces provisional fibronectin and early collagen matrices, transforming the exudative fluid into organizing cellular granulation tissue.

3. Fibrotic Phase (>21 Days)

Structural Remodeling: Observed in a subset of patients with unresolving disease; characterized by extensive collagen deposition, parenchymal architectural distortion, and subpleural cyst or bulla formation.

Microvascular Obliteration: Permanent loss of microvascular beds leads to chronic pulmonary vascular resistance elevation, refractory hypercapnia, and irreversible reductions in static respiratory compliance ( C rs C_{\text{rs}} C rs ​ ).

Mechanical Ventilation Modes: Comparison and Mechanics

Selecting an appropriate mechanical ventilation mode in ARDS balances the necessity of providing reliable alveolar minute ventilation against the hazard of cyclic mechanical stress.

Mechanical Parameter Volume-Controlled Ventilation (VCV) Pressure-Controlled Ventilation (PCV) Pressure Support Ventilation (PSV)

Trigger Time or patient effort (flow/pressure) Time or patient effort (flow/pressure) Patient effort (flow or pressure)

Limit Variable Flow (volume-limited) Pressure (pressure-limited) Pressure (pressure-limited)

Cycle Variable Volume (or inspiratory time) Time (set inspiratory time, T i T_i T i ​ ) Flow (falls to set percentage of peak flow, e.g., 25 % 25\% 25% )

Flow Waveform Constant square or decelerating ramp Exponentially decelerating flow Decelerating flow

Controlled Variable Tidal volume ( V T V_T V T ​ ) is strictly guaranteed Peak inspiratory pressure ( P insp P_{\text{insp}} P insp ​ ) is strictly guaranteed Target pressure level above PEEP is guaranteed

Clinical Hazards Variable and potentially excessive peak and plateau pressures if lung compliance abruptly declines Variable tidal volume ( V T V_T V T ​ fluctuates widely with changes in respiratory compliance or patient effort) Risk of hypoventilation or apnea if patient ventilatory drive ceases; patient-ventilator dyssynchrony

Primary Role in ARDS First-line mode during acute deep sedation/paralysis to enforce lung-protective 6 mL/kg 6\text{ mL/kg} 6 mL/kg PBW Alternative first-line mode; decelerating flow provides homogeneous alveolar recruitment and lower P peak P_{\text{peak}} P peak ​ Weaning phase once acute lung injury and patient-ventilator dyssynchrony have resolved

Ventilator-Induced Lung Injury (VILI)

Inappropriate ventilator settings directly aggravate preexisting alveolar injury, culminating in Ventilator-Induced Lung Injury (VILI) through four distinct mechanisms:

Barotrauma: Gross air leaks (pneumothorax, pneumomediastinum, subcutaneous emphysema) resulting from excessive transalveolar pressure gradients exceeding the structural tension limits of the alveolar wall.

Volutrauma: High end-inspiratory alveolar volume causing regional overdistension and disruption of alveolar-capillary integrity. Volutrauma is driven by absolute volume distension rather than airway pressure alone.

Atelectrauma: Low end-expiratory alveolar volume leading to repetitive cyclic opening, collapse, and reopening of unstable, surfactant-deficient alveoli. The resulting liquid-bridge shear forces strip away the surfactant film and tear the alveolar epithelium.

Biotrauma: Mechanotransduction: physical strain and shear stress activate cellular signaling cascades in alveolar macrophages and epithelial cells, stimulating the release of inflammatory cytokines (IL-1 β \beta β , IL-6, TNF- α \alpha α , CXCL8). These mediators enter the systemic circulation via disrupted capillaries, driving systemic inflammatory response syndrome (SIRS), hemodynamic collapse, and Multi-Organ Dysfunction Syndrome (MODS).

The ARDSNet Lung-Protective Ventilation Strategy

The landmark ARDS Network (ARMA) trial established that ventilating with lower tidal volumes significantly reduces mortality compared to traditional ventilation ( 31.0 % 31.0\% 31.0% vs 39.8 % 39.8\% 39.8% , p = 0.007 p = 0.007 p = 0.007 ).

1. Predicted Body Weight (PBW)

Tidal volume must be calculated strictly according to Predicted Body Weight (PBW) based on patient height and sex, rather than actual body weight. Actual body weight overestimates lung volume—particularly in obese individuals—because lung size correlates with skeletal height, not adipose mass (the "baby lung" concept introduced by Gattinoni, where functional aerated lung in ARDS equals that of a normal 5-to-6-year-old child).

PBW (Males) = 50 + 0.91 × ( Height in cm − 152.4 ) \text{PBW (Males)} = 50 + 0.91 \times (\text{Height in cm} - 152.4) PBW (Males) = 50 + 0.91 × ( Height in cm − 152.4 ) PBW (Females) = 45.5 + 0.91 × ( Height in cm − 152.4 ) \text{PBW (Females)} = 45.5 + 0.91 \times (\text{Height in cm} - 152.4) PBW (Females) = 45.5 + 0.91 × ( Height in cm − 152.4 )

Initial Target: 6 mL/kg 6\text{ mL/kg} 6 mL/kg of PBW (titratable between 4 and 8 mL/kg 4\text{ and }8\text{ mL/kg} 4 and 8 mL/kg PBW based on plateau pressure and pH).

2. Plateau Pressure Limit ( P plat P_{\text{plat}} P plat ​ )

Plateau pressure reflects end-inspiratory static alveolar distending pressure and is measured during a 0.5 -second 0.5\text{-second} 0.5 -second end-inspiratory occlusion hold:

P plat ≤ 30 cm H 2 O P_{\text{plat}} \le 30\text{ cm}\text{H}_2\text{O} P plat ​ ≤ 30 cm H 2 ​ O

If P plat > 30 cm H 2 O P_{\text{plat}} > 30\text{ cm}\text{H}_2\text{O} P plat ​ > 30 cm H 2 ​ O , tidal volume must be decreased by 1 mL/kg 1\text{ mL/kg} 1 mL/kg PBW decrements down to a minimum of 4 mL/kg 4\text{ mL/kg} 4 mL/kg PBW.

3. Driving Pressure ( Δ P \Delta P Δ P )

Amato et al. demonstrated that driving pressure is the physiological parameter most strongly associated with survival in ARDS:

Δ P = P plat − PEEP = V T C rs \Delta P = P_{\text{plat}} - \text{PEEP} = \frac{V_T}{C_{\text{rs}}} Δ P = P plat ​ − PEEP = C rs ​ V T ​ ​

Driving pressure normalizes tidal volume to functional respiratory system compliance ( C rs C_{\text{rs}} C rs ​ ), reflecting the true strain on the aerated "baby lung." Clinicians should maintain Δ P < 14 − 15 cm H 2 O \Delta P < 14-15\text{ cm}\text{H}_2\text{O} Δ P < 14 − 15 cm H 2 ​ O . Reductions in Δ P \Delta P Δ P achieved by adjusting PEEP or V T V_T V T ​ correlate directly with improved hospital survival.

4. PEEP Titration and Permissive Hypercapnia

PEEP Titration: Applied according to high or low PEEP/ F i O 2 F_i\text{O}_2 F i ​ O 2 ​ tables (or decremental PEEP titration following a recruitment maneuver) to maintain alveolar patency at end-expiration, prevent atelectrauma, and reduce intrapulmonary shunt.

Permissive Hypercapnia: Because low tidal volume ventilation reduces alveolar minute ventilation, P a CO 2 P_a\text{CO}_2 P a ​ CO 2 ​ is permitted to rise, accepting an arterial pH as low as 7.20 − 7.25 7.20-7.25 7.20 − 7.25 .

Absolute and Relative Contraindications to Permissive Hypercapnia:

Elevated intracranial pressure (ICP) or acute traumatic brain injury (hypercapnia causes cerebral vasodilation, increasing intracranial volume and pressure);

Severe pulmonary arterial hypertension or acute right ventricular failure (hypercapnia and acidemia trigger intense pulmonary vasoconstriction, precipitating acute cor pulmonale);

Severe hemodynamic instability or uncorrected metabolic acidosis;

Acute coronary syndrome (acidemia reduces myocardial contractility and lowers dysrhythmia thresholds).

  • Evidence-Based Adjunctive Therapies in Severe ARDS Moderate-to-Severe ARDS (P/F < 150 mmHg on PEEP >= 5)
  • ├── Lung-Protective Ventilation (VT 6 mL/kg PBW, Pplat <= 30, Driving Pressure < 14)
  • ├── Early Prone Positioning (>= 16 hours/day) ────── [PROSEVA Trial: Proven Mortality Reduction]
  • ├── Neuromuscular Blockade (selected patients) ──── [ROSE 2019: No Routine Mortality Benefit]
  • ├── Inhaled Pulmonary Vasodilators (iNO / Epoprostenol) ── [Improves Oxygenation; No Mortality Benefit]
  • └── Refractory Hypoxemia (P/F < 80 mmHg) ────────── [VV-ECMO: EOLIA / CESAR Criteria]
  • 1. Prone Positioning (The PROSEVA Trial)

The PROSEVA trial demonstrated that in patients with severe ARDS ( P a O 2 / F i O 2 < 150 mmHg P_a\text{O}_2/F_i\text{O}_2 < 150\text{ mmHg} P a ​ O 2 ​ / F i ​ O 2 ​ < 150 mmHg with PEEP ≥ 5 cm H 2 O \ge 5\text{ cm}\text{H}_2\text{O} ≥ 5 cm H 2 ​ O , F i O 2 ≥ 0.60 F_i\text{O}_2 \ge 0.60 F i ​ O 2 ​ ≥ 0.60 ), early and prolonged prone positioning for at least 16 consecutive hours per day reduced 28-day mortality from 32.8 % 32.8\% 32.8% to 16.0 % 16.0\% 16.0% ( p < 0.001 p < 0.001 p < 0.001 ) and 90-day mortality from 41.0 % 41.0\% 41.0% to 23.6 % 23.6\% 23.6% .

Physiological Mechanisms:

Homogenization of Transpulmonary Pressure: In the supine position, the weight of ventral lung tissue, the heart, and abdominal contents causes a steep ventral-to-dorsal pleural pressure gradient, compressing dependent dorsal lung regions. In the prone position, the vertical gradient of transpulmonary pressure ( P tp = P alv − P pl P_{\text{tp}} = P_{\text{alv}} - P_{\text{pl}} P tp ​ = P alv ​ − P pl ​ ) becomes uniform, leading to homogeneous alveolar inflation.

Ventilation-Perfusion ( V / Q V/Q V / Q ) Matching: Pulmonary perfusion remains preferentially distributed to dorsal lung segments regardless of body position due to vascular anatomical architecture. By opening dependent dorsal alveoli while maintaining dorsal blood flow, ventilation-perfusion mismatch and intrapulmonary shunting are substantially reduced.

Reduced Lung Strain: By recruiting dorsal units, the volume of aerated lung increases, lowering regional driving pressure and mitigating VILI.

2. Neuromuscular Blockade (The ACURASYS and ROSE Trials)

ACURASYS Trial: Early 48-hour continuous infusion of cisatracurium besylate in severe ARDS ( P a O 2 / F i O 2 < 150 mmHg P_a\text{O}_2/F_i\text{O}_2 < 150\text{ mmHg} P a ​ O 2 ​ / F i ​ O 2 ​ < 150 mmHg ) improved adjusted 90-day survival and increased ventilator-free days without inducing ICU-acquired muscle weakness.

Mechanisms: Complete paralysis eliminates patient-ventilator dyssynchrony (e.g., breath-stacking, double triggering, reverse triggering), abolishes violent transpulmonary pressure swings (such as occult pendelluft—intrapulmonary gas movement between lung units), and lowers total-body systemic oxygen consumption.

ROSE (PETAL Network) Trial: When light sedation was protocolized, early continuous neuromuscular blockade showed no mortality difference compared to a strategy of deep sedation with targeted, intermittent paralysis. The 2023 ESICM ARDS guideline recommends against routine continuous neuromuscular blockade; a short course (about 24 − 48 hours 24-48\text{ hours} 24 − 48 hours ) is reserved for selected patients with persistent patient-ventilator dyssynchrony, refractory hypoxaemia, or high driving pressure despite optimised analgesia and sedation.

3. Inhaled Pulmonary Vasodilators

Inhaled Nitric Oxide (iNO) and Inhaled Prostacyclin (Epoprostenol): Delivered directly into the inspiratory limb of the breathing circuit. These agents act selectively on smooth muscle in ventilated alveolar units, causing localized vasodilation.

Physiology: Redirects pulmonary blood flow away from non-aerated, consolidated lung regions toward well-ventilated units, decreasing physiological shunt fraction and improving arterial oxygenation without inducing systemic hypotension.

Clinical Outcome: Meta-analyses show rapid, temporary improvements in P a O 2 / F i O 2 P_a\text{O}_2/F_i\text{O}_2 P a ​ O 2 ​ / F i ​ O 2 ​ , but no reduction in overall mortality or duration of mechanical ventilation . Routine use is reserved as a rescue bridge for refractory hypoxemic crises.

4. Extracorporeal Membrane Oxygenation (ECMO)

Venovenous (VV) ECMO: Indicated for severe, refractory hypoxemic respiratory failure where lung-protective ventilation cannot maintain gas exchange without hazardous airway pressures. The EOLIA trial entry criteria, applied despite optimised ventilation (including prone positioning where possible), were P a O 2 / F i O 2 < 50 mmHg P_a\text{O}_2/F_i\text{O}_2 < 50\text{ mmHg} P a ​ O 2 ​ / F i ​ O 2 ​ < 50 mmHg for > 3 hours >3\text{ hours} > 3 hours , P a O 2 / F i O 2 < 80 mmHg P_a\text{O}_2/F_i\text{O}_2 < 80\text{ mmHg} P a ​ O 2 ​ / F i ​ O 2 ​ < 80 mmHg for > 6 hours >6\text{ hours} > 6 hours , or p H < 7.25 pH < 7.25 p H < 7.25 with P a CO 2 ≥ 60 mmHg P_a\text{CO}_2 \ge 60\text{ mmHg} P a ​ CO 2 ​ ≥ 60 mmHg for > 6 hours >6\text{ hours} > 6 hours .

Venoarterial (VA) ECMO: Drains venous blood and returns oxygenated blood to the arterial system, providing simultaneous circulatory and respiratory support in combined acute cardiopulmonary failure (e.g., refractory cardiogenic shock with ARDS or acute massive pulmonary embolism).

Clinical Pearls and Exam Traps

Actual vs Predicted Body Weight Trap: Never use actual body weight to calculate tidal volume in ARDS. In an obese patient weighing 120 kg 120\text{ kg} 120 kg with a PBW of 70 kg 70\text{ kg} 70 kg , setting 6 mL/kg 6\text{ mL/kg} 6 mL/kg based on actual weight ( 720 mL 720\text{ mL} 720 mL ) yields an effective tidal volume of > 10 mL/kg >10\text{ mL/kg} > 10 mL/kg PBW, producing massive volutrauma and accelerating patient mortality.

Peak vs Plateau Pressure Distinction: P peak P_{\text{peak}} P peak ​ reflects total airway resistance plus respiratory system elastance ( P peak = Flow × R aw + P plat P_{\text{peak}} = \text{Flow} \times R_{\text{aw}} + P_{\text{plat}} P peak ​ = Flow × R aw ​ + P plat ​ ). A high P peak P_{\text{peak}} P peak ​ with a normal P plat P_{\text{plat}} P plat ​ indicates an airway resistance problem (e.g., endotracheal tube kinking, bronchospasm, mucus plugging). A high P plat P_{\text{plat}} P plat ​ indicates decreased thoracic or lung compliance (e.g., worsening ARDS, pneumothorax, abdominal compartment syndrome).

Prone Positioning Timing: Prone positioning must be implemented early (within the first 24 − 48 hours 24-48\text{ hours} 24 − 48 hours of moderate-to-severe ARDS diagnosis) and continued for at least 16 consecutive hours 16\text{ consecutive hours} 16 consecutive hours per session. Intermittent brief prone turns ( < 12 hours <12\text{ hours} < 12 hours ) do not confer a mortality benefit.